The major Japanese firm says decision prompted by desire to focus more resources on late-stage clinical candidates and core therapeutic areas, while expanding deals.

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.

News and views from day 3 of the BIO annual meeting include business development insights, such as Sanofi's global head of BD Alban De La Sabliere's promise that big pharma has no hidden agenda and an AbbVie BD exec's observations that lower company valuations have not led to lower asking prices. Also, BIO chairman and Nkarta CEO Paul Hastings' optimism that biotech will rebound and Venus Williams' Sjogren's disease story draws a crowd.